## Can Liu

## List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/11908725/publications.pdf Version: 2024-02-01



CANLLIL

#	Article	IF	CITATIONS
1	Modelâ€Based Cellular Kinetic Analysis of Chimeric Antigen Receptorâ€T Cells in Humans. Clinical Pharmacology and Therapeutics, 2021, 109, 716-727.	4.7	49
2	Speed and Location Both Matter: Antigen Stimulus Dynamics Controls CAR-T Cell Response. Frontiers in Immunology, 2021, 12, 748768.	4.8	4
3	Mechanism of activation for the sirtuin 6 protein deacylase. Journal of Biological Chemistry, 2020, 295, 1385-1399.	3.4	30
4	Mathematical modeling of the heterogeneous distributions of nanomedicines in solid tumors. European Journal of Pharmaceutics and Biopharmaceutics, 2019, 142, 153-164.	4.3	10
5	Dynamic metrics-based biomarkers to predict responders to anti-PD-1 immunotherapy. British Journal of Cancer, 2019, 120, 346-355.	6.4	16
6	A Multiscale Physiologically-Based Pharmacokinetic Model for Doxorubicin to Explore its Mechanisms of Cytotoxicity and Cardiotoxicity in Human Physiological Contexts. Pharmaceutical Research, 2018, 35, 174.	3.5	33
7	Differential effects of pravastatin on the pharmacokinetics of paroxetine in normal and diabetic rats. Xenobiotica, 2017, 47, 20-30.	1.1	5
8	Tet2 loss leads to hypermutagenicity in haematopoietic stem/progenitor cells. Nature Communications, 2017, 8, 15102.	12.8	88
9	Catalytic Site-Selective Acylation of Carbohydrates Directed by Cation– <i>n</i> Interaction. Journal of the American Chemical Society, 2017, 139, 4346-4349.	13.7	75
10	Acute liver failure impairs function and expression of breast cancerâ€resistant protein ( <scp>BCRP</scp> ) at rat blood–brain barrier partly via ammoniaâ€ <scp>ROS</scp> â€ <scp>ERK</scp> 1/2 activation. Journal of Neurochemistry, 2016, 138, 282-294.	3.9	25
11	Decreased exposure of atorvastatin in diabetic rats partly due to induction of hepatic Cyp3a and Oatp2. Xenobiotica, 2016, 46, 875-881.	1.1	17
12	Co-administration of paroxetine increased the systemic exposure of pravastatin in diabetic rats due to the decrease in liver distribution. Xenobiotica, 2015, 45, 794-802.	1.1	3
13	High-fat diet enhanced retinal dehydrogenase activity, but suppressed retinol dehydrogenase activity in liver of rats. Journal of Pharmacological Sciences, 2015, 127, 430-438.	2.5	19
14	Chiral Catalyst-Directed Dynamic Kinetic Diastereoselective Acylation of Lactols for <i>De Novo</i> Synthesis of Carbohydrate. Organic Letters, 2015, 17, 5272-5275.	4.6	43
15	Combined Contribution of Increased Intestinal Permeability and Inhibited Deglycosylation of Ginsenoside Rb1 in the Intestinal Tract to the Enhancement of Ginsenoside Rb1 Exposure in Diabetic Rats after Oral Administration. Drug Metabolism and Disposition, 2015, 43, 1702-1710.	3.3	33
16	Prediction of Drug Disposition in Diabetic Patients by Means of a Physiologically Based Pharmacokinetic Model. Clinical Pharmacokinetics, 2015, 54, 179-193.	3.5	25
17	Co-administration of paroxetine and pravastatin causes deregulation of glucose homeostasis in diabetic rats via enhanced paroxetine exposure. Acta Pharmacologica Sinica, 2014, 35, 792-805.	6.1	19
18	Hyperammonemia enhances the function and expression of Pâ€glycoprotein and Mrp2 at the blood–brain barrier through <scp>NF</scp> â€₽B. Journal of Neurochemistry, 2014, 131, 791-802.	3.9	30

Can Liu

#	Article	IF	CITATIONS
19	Decreased exposure of simvastatin and simvastatin acid in a rat model of type 2 diabetes. Acta Pharmacologica Sinica, 2014, 35, 1215-1225.	6.1	27
20	Association of GLP-1 secretion with anti-hyperlipidemic effect of ginsenosides in high-fat diet fed rats. Metabolism: Clinical and Experimental, 2014, 63, 1342-1351.	3.4	27
21	Increased Levels of Fatty Acids Contributed to Induction of Hepatic CYP3A4 Activity Induced by Diabetes — In Vitro Evidence From HepG2 Cell and Fa2N-4 Cell Lines. Journal of Pharmacological Sciences, 2014, 124, 433-444.	2.5	24
22	A Mechanistic Physiologically Based Pharmacokinetic-Enzyme Turnover Model Involving both Intestine and Liver to Predict CYP3A Induction-Mediated Drug–Drug Interactions. Journal of Pharmaceutical Sciences, 2013, 102, 2819-2836.	3.3	29
23	Pâ€glycoprotein and multidrug resistanceâ€associated protein 2 are oppositely altered in brain of rats with thioacetamideâ€induced acute liver failure. Liver International, 2013, 33, 274-282.	3.9	20
24	Increased glucagon-like peptide-1 secretion may be involved in antidiabetic effects of ginsenosides. Journal of Endocrinology, 2013, 217, 185-196.	2.6	55
25	Induction of multidrug resistance-associated protein 2 in liver, intestine and kidney of streptozotocin-induced diabetic rats. Xenobiotica, 2012, 42, 709-718.	1.1	13